A Study of AMG 337 in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Men or women ≥ 18 years old * Subjects must have a pathologically documented, definitively diagnosed, advanced solid tumor * Subjects with primary central nervous system (CNS) tumors or metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible providing they meet all of the following criteria: a) residual neurological symptoms grade ≤ 1; 2) no dexamethasone treatment; and c) follow-up MRI shows no new lesions appearing * Measurable disease per RECIST guidelines (subjects with non-measurable, but evaluable disease are also eligible for the dose escalation portion of the study) * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 * Competent to sign and date an Institutional Review Board approved informed consent form * Adequate hematologic and renal function as determined by laboratory blood and urine tests Exclusion Criteria: * Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and continuing for 2 weeks (for women) and 12 weeks (for men) after receiving the last dose of study drug. * Women who are lactating/breastfeeding or planning to become pregnant during the duration of the study * History of bleeding diathesis * Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association \> class II), unstable angina, or unstable cardiac arrhythmia requiring medication, or uncontrolled hypertension * A baseline ECG QTc \> 470 ms * Active infection requiring (IV) antibiotics within 2 weeks of study enrollment * Significant gastrointestinal disorder(s), in the opinion of the investigator, that may influence drug absorption * Known positive test for HIV * Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests * Anti-tumor therapy within 28 days of study day 1 including chemotherapy, antibody therapy, retinoid therapy, or other investigational agent * Major surgery within 30 days of study day 1 * Any co-morbid medical disorder that may increase the risk of toxicity, in the opinion of the investigator or sponsor